COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with ...
Please provide your email address to receive an email when new articles are posted on . Treating patients who have primary biliary cholangitis and cirrhosis with seladelpar — a peroxisome proliferator ...
In a series of posts I want to explore the interplay between basic biology, which looks at the natural world to learn about how life works, and synthetic biology, which studies what is not found in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback